A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

Inclusion Criteria:

* Patients participated voluntarily and signed informed consent；
* PTCL confirmed by histopathology；
* There must be at least one evaluable or measurable lesion that meets Lugano2014 criteria；
* The ECOG score is 0 to 1；
* ANC≥1.5×10\*9/L，PLT≥75 × 10\*9/L；HB≥80 g/L；TBIL≤1.5ULN；ALT or AST≤2.5 ULN； Scr≤1.5ULN；
* Use contraception during treatment and for one year after the end of treatment.

Exclusion Criteria:

* Patients with central nervous system (CNS) involvement and/or hemophagocytic syndrome；
* The estimated survival time is less than 6 months；
* History of allergy to anthracyclines or liposomes; Previous recipients of mitoxantrone or mitoxantrone liposome;Previous treatment with doxorubicin or other anthracyclines had a cumulative dose of doxorubicin \> 360 mg/m2（For other anthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin, and the maximum cumulative dose of liposomal doxorubicin is 2460mg/m2）；
* The use of Chidamide is contraindicated;
* Impaired heart function or significant heart disease;
* Hepatitis B, hepatitis C active stage infection;
* Had undergone major surgery within 4 to 6 weeks prior or expected to undergo major surgery during the study;
* severe infection;
* Poorly controlled high blood pressure or diabetes;
* A history of active visceral bleeding within the previous 3 months
* A history of malignancy within five years;
* History of mental illness;
* A history of substance abuse or dependence;
* pregnant or lactating woman;
* The investigators did not consider it appropriate to participate in this study.